Oventus Medical Limited announced a succession plan which would see Dr. Chris Hart transition out of the role of Managing Director. In his new role, Dr. Hart while remaining an Executive Director, will focus on ensuring a smooth transition for Mr. Cox, and will, in his new role as Chief Scientific Officer, lead Oventus' scientific "first line therapy" initiative, leading scientific and clinical research projects designed to position the O2Vent Optima technology as the first choice for patients and clinicians for the treatment of Obstructive Sleep Apnea. The new roles will take effect on 1 February 2022.

From 1 June 2022, Dr. Hart will transition to Non-Executive Director of Oventus and will also lead the Company's Scientific Advisory Board.